BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel
Optimer Pharmaceuticals, Inc. (NQ: OPTR)
12.78 USD  UNCHANGED
Last Price  /  Updated: 4:00 PM EDT, Oct 23, 2013  /  Add to My Watchlist      
(OPTR) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
Related Wikinvest articles
April 24, 2014
(Stock Blog Hub, 5/16/13)
Optimer Pharmaceuticals (OPTR) received encouraging news recently when the Australian regulatory body (Australian Therapeutic Goods Administration) cleared its drug...(read more)
Courtesy of Benzinga. Optimer Pharmaceuticals (NASDAQ: OPTR) today announced its Board of Directors has appointed Hank McKinnell as its...(read more)
(, 9/14/11)
Per the recent trade of the week shopping list, we have initiated some more long trades this week for the first time in a while.  It is great to finally start using some technicals...(read more)
Optimer Pharmaceuticals (OPTR) Company Overview

Optimer Pharmaceuticals Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. The company is currently focused on the development of products that treat gastrointestinal (GI) infections and related diseases where current therapies have limitations, including diminished efficacy, serious adverse side effects, drug-to-drug interactions, difficult patient compliance and bacterial resistance. Optimer has two late-stage anti-infective product candidates, Difimicin and Prulifloxacin. Difimicin (OPT-80) is an antibiotic currently in a phase III registration trial for the treatment of Clostridium difficile-associated diarrhea (CDAD), the most common nosocomial, or hospital-acquired, diarrhea. Prulifloxacin is an antibiotic currently in two phase III trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Optimer is also developing additional product candidates using its proprietary technology, including Optimer One-Pot Synthesis (OPopS) drug discovery platform. The following table summarizes the major clinical/preclinical drug candidates:

Product Candidate

(Read more at Wikinvest )

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here